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Abstract
Background: Larviciding for malaria control can contribute to an Integrated Vector Management (IVM) approach.
This intervention is currently supported in settings where breeding habitats are ‘few, fixed, and findable’, such as
urban areas of sub-Saharan Africa, but the knowledge base regarding the cost-effectiveness of larviciding is
non-existent.
Methods: Programme costs and effectiveness data were collected from the Dar es Salaam Urban Malaria Control
Programme in Tanzania. Cost-effectiveness ratios (CER) were estimated from the provider and societal perspectives
for standard indicators using different malaria transmission scenarios.
Results: CER for microbial larviciding were highly dependent on the assumed baseline malaria incidence rates.
Using the societal perspective, net CER were estimated (in 2012 US dollars) at $43 (95% uncertainty intervals [UI]:
$15-181) per disability-adjusted life year averted (DALY) when malaria incidence was 902 infections per 1,000
individuals, increasing to $545 (95% UI: $337-1,558) per DALY at an incidence of 122 per 1,000. Larviciding was
shown to be cost-effective in Tanzania for incidences as low as 40 infections per 1,000 people per year.
Conclusion: This is believed to be the first study to estimate the cost-effectiveness of larviciding for urban malaria
control in sub-Saharan Africa. The results support the use of larviciding as a cost-effective intervention in urban
areas and managers of national malaria control programme should consider this intervention as part of an IVM
approach.
Keywords: Malaria, Cost-effectiveness, Economic evaluation, Integrated vector management, Larval source
management, Larviciding, Bacillus sphaericus, Bacillus thuringiensis var. israelensis
Background
Integrated Vector Management (IVM), as endorsed by
the World Health Organization (WHO) [1], emphasizes
rational decision-making, intersectoral collaboration,
and the combination of different tools for vector control.
Strategies included in an IVM approach should be
based on local eco-epidemiological conditions with
the aim of improving ‘the efficacy, cost effectiveness,
ecological soundness and sustainability of interventions’
[2]. Currently, insecticide-treated nets (ITNs) and in-
door residual spraying (IRS) are among the most
widely used vector control methods in sub-Saharan
Africa (SSA) [3]. The scaling-up of these two interven-
tions during the last decade, coupled with improved
access to early diagnosis and prompt treatment, has
contributed to the important decline in malaria bur-
den on this continent [4,5]. Nevertheless, IRS and
ITNs could be insufficient to achieve the long-term
goal of malaria elimination in much of SSA [6,7] and
current gains might not be sustained ‘without adapt-
ing to the changing threats to and opportunities for re-
ducing transmission’ [3].
An additional strategy for malaria control, Larval
Source Management (LSM), the management of poten-
tial mosquito larval habitats, has had historical successes
[8-12] and was one of the primary methods for malaria
control until the 1950s, when IRS with DDT became the
preferred control method [13]. Environmental manage-
ment and larviciding could nevertheless play a role when
other vector control interventions have achieved their
maximum practical impact and/or in the malaria pre-
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tematic review of LSM interventions has shown that,
under selected circumstances in various Asian and
African settings, LSM can decrease malaria burden [14].
LSM should only be considered in specific contexts,
however, as this type of intervention is likely to be most
effective in areas where larval habitats are ‘few, fixed,
and findable’ [15]. In SSA, these conditions are likely to
be found in settings of focal and low to moderate trans-
mission, such as urban environments, desert fringes,
high altitudes, and some densely populated rural areas
[13]. Further, LSM could contribute to IVM when
dominant vectors are biting and/or resting outdoors
(exophagic and exophilic behaviour) and to help manage
insecticide resistance [13]. The knowledge base regard-
ing the cost-effectiveness of LSM interventions is scarce,
however. Environmental management was the subject of
only one cost-effectiveness study that was based on the
analysis of a colonial-era integrated malaria control
programme carried out in copper mining communities
of former Northern Rhodesia (present day Zambia) [16].
It is believed that only one cost analysis of larviciding
programmes has been performed to date [17,18] and the
cost-effectiveness of this type of intervention remains to
be assessed. This adds to the paucity of data on the
cost-effectiveness of vector control interventions in
urban areas.
The aim of this paper is thus to estimate the cost-
effectiveness of larviciding for malaria control in urban
areas of SSA, drawing from the recent large-scale
community-based larviciding programme carried out by
the Urban Malaria Control Programme (UMCP) in
Dar es Salaam (United Republic of Tanzania) [19-24]. Cost-
effectiveness ratios (CER) per malaria infection averted,
malaria deaths prevented, and disability-adjusted life years
(DALY) avoided are reported from both provider and soci-
etal perspectives for different transmission intensity scenar-
ios and microbial larvicide formulations.
Methods
Dar es Salaam urban malaria control programme
This economic analysis is based on a large-scale larvicid-
ing intervention conducted in urban Dar es Salaam,
Tanzania’s largest city and economic capital. The domin-
ant malaria vectors are Anopheles gambiae s.s. and
Anopheles funestus. These vectors transmit Plasmodium
falciparum who is responsible for more than 90% of in-
fections [25]. The principal types of breeding habitats
encountered in Dar es Salaam are: drains, borrow pits,
ponds, aquatic habitats associated with urban agricul-
ture, and swamps [26]. Malaria transmission is year-
round but exhibits seasonal variations related to the two
rainy seasons: the short rains of October to December
and the long rains of March to May.
The Urban Malaria Control Programme (UMCP) was
launched in 2004 with the goal of developing a sustain-
able larviciding intervention as part of an integrated
malaria strategy [21,27,28]. The UMCP targeted 15
urban wards, five in each of the three municipalities
that composed Dar es Salaam (Temeke, Ilala, and
Kinondoni), covering 56 km
2 of the city and encom-
passing a population of 610,000 residents (2002 cen-
sus) [29]. Larviciding was operationalized through a
vertically managed community-based delivery system
[17]. Routine mosquito surveillance and control was
delegated to modestly paid community members called
Community-Owned Resource Person (CORP) [21,27,28].
Larviciding was initiated in March of 2006 in three of the
15 UMCP wards (one in each municipality), and subse-
quently scaled-up to nine wards in May of 2007, and to
the entire study region in April of 2008.
Costing
Costing data for this study were extracted from the
UMCP cost analysis described in Worrall [18] and
Worrall and Fillinger [17]. Both studies adopted an
‘ingredients approach’ [30] to analyse costs, which is
consistent with methods used for costing large-scale
ITN and IRS programmes. The cost analysis was in-
formed by data from the first phase of larviciding, when
the intervention was operational in three wards, and
mapping and larval surveillance activities were being
carried out in the remaining wards [17,18]; thus oper-
ational costs from these three wards were extrapolated
for the entire study area. All resources used and the op-
portunity costs of existing inputs were taken into ac-
count. Specifically, the costs of the intervention include:
community sensitization, training (including international
consultants), field personnel, ward supervisors, larvicide
purchase and distribution, transportation, materials, office
space and furniture (including overheads), storage, and
monitoring and evaluation (note that all research costs
were excluded). Costs of capital items were spread over
their estimated useful life and annualized using a 3% dis-
count rate.
The UMCP used microbial larvicides for vector con-
trol manufactured by Valent BioSciences Corp. (Illinois,
USA). The active ingredient of this product is a bio-
logical agent and is available in two formulations: 1)
custom granule (CG) for hand application (Bacillus
sphaericus; VectoLex®), and 2) water dispersible granule
(WG) for liquid application (Bacillus thuringiensis var.
israelensis; VectoBac®). Differences in international toxic
units per milligrams of product between the two formu-
lations result in higher costs for the CG formulation
[17]. Although the UMCP made the programmatic deci-
sion to routinely apply CG, the impact on CERs of using
the less expensive WG formulations will be explored.
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tion was presumed to be part of an ongoing programme
and costs were, therefore, aggregated over 10 years (2004–
2014) - 2004 being the pre-implementation phase when
ward mapping, programme planning, and training oc-
curred. Larviciding was operationalized starting in 2005.
Other assumptions include that the intervention would
not be scaled-up beyond UMCP wards and that the only
increase in the number of persons protected would be due
to population growth. To this end, ward-specific popula-
tion counts from the 2002 and 2012 censuses were used
and it was found that population growth averaged 1.62%
over that period: from 610,000 in 2002 to 716,000 in 2012
[31,32]. International technical consultants were assumed
to be required for the first 5 years of the programme, time
after which it was considered that capacity building, tech-
nical support, and troubleshooting of the intervention
would no longer require international expertise. Results
are reported based on the economic costs of the interven-
tion as it is considered more appropriate for comparisons
of interventions’ efficiency than using financial costs. All
prices have been adjusted to 2012 US dollars (USD) using
the US Gross Domestic Product (GDP) deflator [33] after
being converted from local currency using average ex-
change rates for the year they were disbursed.
Effectiveness data
The main clinical outcome reported by the UMCP is
the prevalence of malaria infection, as determined by
Giemsa-stained thick smear microscopy. Initial results
from the first phase of the larval control intervention,
restricted to children under five years of age (N =
4,450), suggested that the odds of malaria infection
were decreased by 72% [27]. Further, anopheline larval
abundance has been shown to be reduced by 96%
during this same time period [21]. Analyses including
individuals of all ages and using data from all phases
of the larviciding intervention’s rollout (N =64,537)
have shown that the odds of malaria infection were
21% lower for individuals living in larviciding wards
(Odds Ratio=0.79; 95% Credible Intervals (CrI): 0.66-
0.93) [28]. This logistic regression model was re-fitted
in order to provide an effect size estimate on the rela-
tive risk scale. This yielded a prevalence ratio of 81%
(95% CrI: 0.70-0.94). This effect size measure provides
ac o n s e r v a t i v ea p p r o x i m a t i o no ft h er a t er a t i o[ 3 4 ]a n d
will be used to estimate the number of infections
averted.
Health outcomes
CERs are reported for the following health outcomes:
malaria infections averted, malaria-associated deaths
prevented, and disability-adjusted life years (DALY)
avoided. One limitation of the UMCP data is that it
collected information on prevalent cases, not incident
ones. In order to estimate these three health out-
comes, however, one needs a measure of incidence
[35]. A two-component mixture of continuous-time
Markov Chains was used to calculate incidence rates
from UMCP data in these analyses (available from
Castro et al.[ 3 6 ] ) .
Number of deaths prevented was estimated by multi-
plying the number of infections averted by the propor-
tion of malaria cases found to be symptomatic and the
case fatality rate. Of all prevalent malaria cases recorded
by the UMCP, only 17% reported either having had a
fever in the last two weeks before the survey or were found
to have a body temperature higher than 37.5° Celsius at the
time of the interview. Further, a clear relationship between
age of prevalent malaria cases and occurrence of fever
was not observed. For this reason, it was decided to
assume that the proportion of new infections that
would contribute malaria morbidity would remain
constant across age groups. Malaria case fatality rate
in the city of Dar es Salaam was available for 2006
from official Ministry of Health statistics. The re-
ported case fatality rate of 0.63% (among symptomatic
cases presenting at health facilities) is about a third of
the average for mainland Tanzania (1.82%) [37].
DALYs were calculated by combining malaria morbid-
ity and mortality. Years of life lost due to disability were
obtained by multiplying the number of cases prevented
by the condition’s disability weight and the average dur-
ation of that condition. The approach used by the 2010
update of the Global Burden of Disease (GBD) was
adopted [38,39] and, accordingly, age weighting and dis-
counting of DALYs were not applied. Detailed descrip-
tion of the calculations can be found in Additional file 1.
Provider’s resources savings
The provider’s perspective takes the viewpoint of the
Tanzanian Ministry of Health and Social Welfare. Costs
savings per malaria infection averted were estimated by
taking into account 1) the proportion of symptomatic
individuals that seek treatment at a health facility, 2) the
proportion treated as outpatient, 3) the proportion
diagnosed with microscopy, 4) the costs of diagnosing
malaria using microscopy, 5) the cost of diagnosing mal-
aria using a rapid diagnostic test (RDT), 6) the cost
of treating an uncomplicated falciparum malaria with
artemether-lumefantrine, 7) the cost of diagnostic and
hospitalization of a complicated falciparum malaria
case treated with intramuscular quinine dihydrochlor-
ine, and 8) the proportion of symptomatic individuals
seeking care through community health workers. Fi-
nally, any user fees for diagnosis and treatment that
would be collected by health facilities were subtracted
from costs savings.
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provider’s cost of treating one symptomatic case of
malaria was estimated to be of $5.15 (17% of malaria
infections were assumed to be symptomatic). This lat-
ter amount was used to aggregate costs savings over
the 10-year duration of the larviciding programme and
to discount savings occurring in the future at a 3%
rate. Detailed information on the cost function used
can be found in Additional file 1.
Society’s resources savings
It has been argued that the most relevant reference case
in economic evaluations should reflect the societal per-
spective, where all costs and consequences of the inter-
vention are aggregated without regards to whom they
accrue [30,40]. In Tanzania, it was estimated that 55% of
all treatment costs of malaria in children under five
years of age were borne by the household [41]. To esti-
mate household costs in Dar es Salaam, the framework
developed by Sicuri et al. [41] was generalized to
individuals of all ages. Specifically, treatment-seeking
behaviours, user fees, medicine costs, transportation
costs, productivity losses due to clinical cases (or car-
ing for sick children) of malaria, anemia, and neuro-
logical sequelae, and funeral costs were taken into
account. The indirect costs per malaria infection
(asymptomatic and symptomatic) and per death were
estimated at $1.39 and $40.39, respectively (a detailed
description of calculations can be found in Additional
file 1). These costs were added to the provider’sc o s t s
savings to obtain the resources that would have been
saved, from the societal perspective, for each infection
averted.
The opportunity costs incurred by community mem-
bers as a result of the larviciding intervention were not
captured. Accounting for these costs would have negli-
gible impact on the results of this economic evaluation,
as it would only involve taking into account time to
allow UMCP teams to access properties where breeding
habitats could be found [17].
Cost-effectiveness scenarios
A central feature of any cost-effectiveness analysis is the
definition of the alternative to the studied intervention.
WHO recommends a state of transmission without any
intervention as the alternative [35]. This might not be
the most realistic scenario as larviciding should be used
as part of an IVM approach [1], in conjunction with
other appropriate vector control measures [13]. To cir-
cumvent this issue and to enable generalization of these
results, CERs were calculated as a function of incidence
and the detailed results are presented considering three
different scenarios:
– Scenario #1: Uses the baseline incidence for the
year 2005, when malaria transmission was highest.
The estimated incidence for that year was of 902
infections per 1,000 people per year that would
result in 153 clinical malaria episodes per 1,000
people per year (assuming that 17% of cases will be
symptomatic). For urban areas, malaria case
incidence rates in this range have been described as
characteristics of low transmission settings [42,43].
– Scenario #2: This scenario assumes moderate
malaria transmission that corresponds to what
was observed in 2006 in the UMCP, when other
control interventions were being scaled up. Malaria
incidence has been estimated at 227 infections per
1,000 people per year.
– Scenario #3: The last scenario corresponds to
the situation in which other malaria control
interventions have already been scaled-up and
achieved impact. This scenario assumes an annual
malaria infection incidence of 122 infections per
1,000 people per year and is the lowest incidence
recorded during the UMCP in 2008.
Sensitivity analysis
One-way sensitivity analyses were used for parameters
whose choice depends on methodological issues (e.g.,
larviciding formulation). Probabilistic analyses were per-
formed to assess the impact of uncertainty in the effective-
ness parameters, health outcomes, and costs. A Monte
Carlo simulation model was built in R package v.2.15.1
[44] and parameters were re-sampled 100,000 times. The
specific distributions from which the parameters were
drawn are described in Additional file 2. The measure of
dispersion reported for the CERs are the 95% uncertainty
interval (UI) - the 2.5% and 97.5% percentiles of the
Monte Carlo simulations. Finally, the uncertainty sur-
rounding the cost-effectiveness of larviciding was summa-
rized using cost-effectiveness acceptability curves.
Ethical considerations
All UMCP data collection procedures were provided
ethics approval from the Medical Research Coordination
Committee of the National Institute for Medical Re-
search, Ministry of Tanzania (Reference number NIMR/
HQ/R.8a/Vol. IX/279 &234). Similarly, the Harvard
School of Public Health’s Institutional Review Board also
approved the research protocol (Protocol # 20323–101).
Informed consent was obtained from all study partici-
pants or, on behalf of children under 18 years of ages,
from their legal guardians.
Results
The economic costs of the 10-year UMCP larviciding
programme were evaluated at a present value of $5,111,234
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per year (PPPY) was of $0.87. This number is lower than
the economic cost PPPY year of $1.05 estimated by Worrall
and Fillinger [17] because population growth was factored-
in and international consultan t sw e r eo n l yi n c l u d e df o rt h e
first five years of the programme.
The first scenario assumed the highest urban malaria
transmission and resulted in the most optimistic cost-
effectiveness results with 1,178,999 malaria infections
averted over the 10-year programme duration (Table 2).
Larviciding would prevent 1,265 deaths and result in a
total of 65,125 DALYs averted. It was evaluated that
these cases would result in costs savings of $878,301 (at
present value) for the provider (assuming that 17% of in-
fections are symptomatic), and an additional $1,433,425
would be saved from the perspective of the society. The
gross CER has been estimated at $4.3 per infection
averted, $4,040 per death prevented, and $78 per DALY
avoided. Taking into account costs savings, the cost of
the programme per DALY avoided decreased to $65
from the provider’s perspective and to $43 from the so-
cietal perspective.
When considering the second transmission scenario,
the number of infections averted was much smaller
(Table 2). Consequently, the present value of costs saved
by averting cases from the provider’s perspective was of
$220,677 and gross and net CER from both the provider
and societal perspectives were similar. The last scenario
used a very low incidence rate and, as expected, the CER
were the least cost-effective of all scenarios. It was
estimated that larviciding would avert 159,282 malaria
infections. Again, gross CER and net CER from the pro-
vider and societal perspective were of the same order of
magnitude.
One-way sensitivity analyses – Larviciding formulations
If a water dispersible formulation was used, the present
value of the 10-year larviciding programme’s costs would
be reduced to $4,076,908 (20% less than the costs associ-
ated with the custom granule formulation), and the aver-
age economic cost per person protected per year would
be of $0.69. Assuming that the water dispersible formu-
lation has the same efficacy as the custom granule used
by the UMCP, the larviciding programme becomes more
cost-effective (Table 3). In fact, net societal CERs ranged
from $1t o$24 per malaria infection averted, and from
$27 to $428 per DALY averted depending on the scenar-
ios under considerations.
Probabilistic sensitivity analysis
The uncertainty surrounding parameters’ estimates was
explored through a probabilistic sensitivity analysis.
CERs per infection averted, death prevented, and DALY
avoided are presented with their 95% UI in Table 4. Un-
certainty in parameters to calculate costs savings per
malaria cases averted did not have an overwhelming in-
fluence on the CER, as demonstrated by the relatively
high overlap between both gross and net CERs. Because
of the relatively wide credible intervals around the
prevalence ratios for the larviciding intervention (i.e.,
95% CrI: 0.70-0.94) [28], there is about a 4-fold differ-
ence between the 2.5
th and 97.5
th percentiles of the sim-
ulated distributions for the gross CER. Net societal CER
per additional DALY avoided had a 95% uncertainty
interval of $15-181 for the scenario where transmission
was highest, $165-822 for the second scenario and $337-
1,548 for the lowest transmission scenario.
Cost-effectiveness acceptability curves show the pro-
portion of simulations that were cost-effective for a
range of policy-makers’ willingness to pay (Figure 1). For
the scenario where transmission was highest, 95% of
Monte Carlo simulations had a willingness to pay
threshold under $154 for an additional DALY averted
(societal perspective and the custom granule formula-
tion). This number increased to $652 and $1,225 for the
second and third scenarios, respectively. To generalize
these findings, net CERs were computed from the pro-
vider and societal perspectives for a range of incidence
rates. Figure 2 shows that, except for very low incidences
(i.e., <40 infections per 1,000 people per year), larvicid-
ing can be considered cost-effective.
Discussion
This paper presents results from the first economic
evaluation of a large-scale larviciding intervention for
Table 1 Projected economic costs per year and








† $147,882 $147,882 0
2005 (Y01) $600,619 $583,125 637,406
2006 (Y02) $600,619 $566,141 647,447
2007 (Y03) $600,619 $549,652 657,880
2008 (Y04) $600,619 $533,642 668,717
2009 (Y05) $567,366 $489,415 679,973
2010 (Y06) $567,366 $475,160 691,662
2011 (Y07) $567,366 $461,320 703,797
2012 (Y08) $567,366 $447,884 716,394
2013 (Y09) $567,366 $434,839 729,469
2014 (Y10) $567,366 $422,174 743,040
Total $5,954,555 $5,111,234 6,875,784
Note: All prices are in 2012 US dollars.
*Economic costs for Y01-Y04 are higher because it was assumed that
international consultants were required for capacity building, planning,
and trouble-shooting of the intervention.
†Pre-implementation year (Y00) has a 6-month duration.
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cost-effectiveness of larviciding has been shown in this
study to be highly dependent on the assumed baseline
malaria incidence. WHO proposed that interventions with
a CER per DALY averted less than a country’s per capita
Gross Domestic Product (GDP) could be regarded as ‘very
cost-effective’ and those for which the cost-effectiveness is
less than three times the country’s per capita GDP as ‘cost-
effective’ [35,45]. Given Tanzania’s per capita GDP of $599
USD (2012), larviciding can be considered very cost-
effective under a wide variety of transmission scenarios.
Even low transmission settings with incidences above 40
infections per 1,000 people per year had CER that fell
within the range of cost-effective interventions. With
regards to the three malaria transmission scenarios, it was
found that, even for the lowest malaria transmission sce-
nario, 61% of Monte Carlo simulations fell below the very
cost-effective threshold (societal perspective) and 98% of
them below the cost-effective threshold.
These analyses also suggest that, if the same efficacy is
assumed for both types of larviciding formulation, using
a water dispersible larvicide is more cost-effective.
Indeed, the provider CER for urban settings with the
highest malaria transmission (Scenario #1) was esti-
mated to be of $49 per DALY avoided (provider’sv i e w -
point), $27 if the societal perspective was adopted. In
practice, the use of both formulations will likely be re-
quired as they are designed for different aquatic
Table 2 Number of cases averted, deaths prevented, disability-adjusted life years averted, and gross and net cost-
effectiveness ratios for the larviciding intervention
Scenarios Total Gross CER* CER* Provider’s perspective CER* Societal perspective
Scenario #1 - Incidence rate of 902 per 1,000
Infection averted 1,178,999 $4.3 $3.6 $2.4
Death prevented 1,265 $4,040 $3,345 $2,213
DALY averted 65,125 $78.5 $65.0 $43.0
Scenario #2 - Incidence rate of 227 per 1,000
Infection averted 296,228 $17.3 $16.5 $15.3
Death prevented 318 $16,077 $15,383 $14,250
DALY averted 16,363 $312.4 $298.9 $276.9
Scenario #3 – Incidence rate of 122 per 1,000
Infection averted 159,282 $32.1 $31.3 $30.1
Death prevented 171 $29,900 $29,206 $28,073
DALY averted 8,798 $580.9 $567.4 $545.4
Note: All prices are in 2012 US dollars.
*CER: Cost-Effectiveness Ratio.
Table 3 Impact on gross and net cost-effectiveness ratios of changing the formulation from custom granule to the less
expensive water dispersible formulation
Scenarios Gross CER* CER* Provider’s perspective CER* Societal perspective
Scenario #1 - Incidence rate of 902 per 1,000
Infection averted $3.5 $2.7 $1.5
Death prevented $3,222 $2,528 $1,395
DALY averted $62.6 $49.1 $27.1
Scenario #2 - Incidence rate of 227 per 1,000
Infection averted $13.8 $13.0 $11.8
Death prevented $12,824 $12,130 $10,997
DALY averted $249.2 $235.7 $213.7
Scenario #3 - Incidence rate of 122 per 1,000
Infection averted $25.6 $24.9 $23.6
Death prevented $23,850 $23,155 $22,023
DALY averted $463.4 $449.9 $427.9
Note: All prices are in 2012 US dollars.
*CER: Cost-Effectiveness Ratio.
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open and non-vegetated breeding habitats, whereas
the custom granule formulation is designed for habi-
tats with emergent vegetation [17]. Hence, depending
on the relative abundance of each type of aquatic habi-
tats, the CER for larviciding should fall within the
CERs calculated for the custom granule and water dis-
persible formulations.
Contextualizing these results is challenging because of
inherent differences of cost-effectiveness studies of other
malaria vector control interventions. A systematic review
of economic evaluations of ITN and IRS programmes
suggested that these interventions are highly cost-
effective in rural areas with a median CER per additional
DALY averted of $27 (range $8.15-110) and $143 (range
$135-150) for ITN and IRS, respectively (in 2009 USD)
[46]. Although this same review reported higher median
financial costs per person protected per year for ITN
of $2.20 and IRS of $6.70 (in 2009 USD) - as com-
pared to $1.05 for the UMCP larviciding programme -
the CERs estimated here are generally higher. A num-
ber of reasons can explain this differential and eco-
nomic evaluations studies of ITN and IRS interventions
conducted in SSA were systematically reviewed to address
this point (see Additional file 3 for details on this system-
atic review).
First, protective efficacy for larviciding is lower than
that of ITN and IRS [47,48]. It was previously estimated
that larviciding reduced the odds of malaria parasitaemia
by 21% in the general population covered by UMCP
Table 4 Impact of probabilistic sensitivity analyses on gross and net cost-effectiveness ratios for the three malaria
incidence scenarios
Scenarios Gross CER* [95% UI
†] CER* Provider perspective [95% UI
†] CER* Societal perspective [95% UI
†]
Scenario #1 - Incidence rate of 902 per 1,000
Infection averted [$3-12] [$2-11] [$1-10]
Death prevented [$2,593-11,110] [$1,879-10,399] [$793-9,346]
DALY averted [$50-215] [$36-201] [$15-181]
Scenario #2 - Incidence rate of 227 per 1,000
Infection averted [$11-47] [$10-11] [$9-46]
Death prevented [$10,321-44,217] [$9,612-43,503] [$8,543-42,438]
DALY averted [$200-856] [$186-842] [$165-822]
Scenario #3 - Incidence rate of 122 per 1,000
Infection averted [$21-88] [$20-87] [$19-86]
Death prevented [$19,195-82,232] [$18,491-81,503] [$17,419-80,444]
DALY averted [$372-1,592] [$358-1,578] [$337-1,558]
Note: All prices are in 2012 US dollars.
*CER: Cost-Effectiveness Ratio.
†95% UI: 95% Uncertainty Interval.
Figure 1 Cost-effectiveness acceptability curves (societal perspective) for larviciding with the custom granule and water dispersible
formulations under the three malaria transmission scenarios.
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economic evaluation can be considered conservative,
however, since larviciding exhibited a greater protective
effect for children under five years of age (i.e., Odds
Ratio = 0.61; 95% Credible Interval: 0.46-0.80) [28].
Although the evidence based on the effectiveness of ITN
is fairly robust [47], a recent Cochrane review of IRS in-
terventions concluded that ‘the number of high quality
trials are too few to quantify the size of effect’ [48].
Nevertheless, out of the seven IRS cost-effectiveness
studies reviewed here, three of them assumed that the
effect size of IRS was equal to that of ITN [49-51]. Thus,
economic analyses of some of the IRS interventions
could be considered imprecise.
Second, economic evaluation of ITN studies almost
exclusively focus on the group of children at highest risk
of malaria morbidity and mortality: children under five
years of age. The ability to deliver ITN to the specific
age group where malaria burden is highest decreases
costs while maximizing health gains. Targeting larvicid-
ing, or to a lesser extent IRS, to children under five years
of age is not in the realm of possibilities as these are
population interventions. Finally, the baseline incidence
rates used in this study comprised both asymptomatic
and symptomatic infections whereas most other studies
assumed that all cases would be symptomatic. In fact,
the three malaria incidence scenarios entail that there
would be between 21 (scenario #3) and 180 symptomatic
cases (scenario #1) per 1,000 individuals per year. The
median baseline malaria case incidence (symptomatic)
used in the reviewed studies was of 900 and of 1,184
infections per year per 1,000 individuals for the ITN and
IRS studies, respectively. Although these incidence rates
fall into a realistic range for most endemic rural areas of
SSA, malaria incidence is assumed to be much lower in
urban areas. This last point is important because,
although the costs of ITN and IRS programmes should
remain relatively stable in urban areas, lower malaria in-
cidence rates would reduce the number of DALY averted
and increase CERs of these interventions. The same can
be said of malaria case fatality rates that are generally
lower in urban areas where prompt access to diagnostic
and early treatment services are generally easier. This
partly explains why the CER per death averted estimated
for larviciding in urban Dar es Salaam is higher than the
one reported for ITN and IRS in rural areas [46]. Im-
portantly, the reviewed studies were almost exclusively
conducted in rural areas. The question of which malaria
control intervention is most cost-effective in urban set-
tings, therefore, remains an open one.
Four potential methodological limitations of this
study need to be acknowledged. The first concerns the
generalizability of these results. This economic evaluation
concerns a single larviciding programme in Dar es Salaam,
where the costs were extrapolated from the first phase of
larviciding, when only three out of the 15 wards where
carrying-out the intervention [17]. If density of larval habi-
tats in the other wards were higher or lower than that in
these three wards, costs could have been under- or overes-
timated. Further, our results are likely to be generalizable
only to other urban areas with similar malaria epidemi-
ology. The estimated net CERs, that take into account
Figure 2 Net cost-effectiveness of larviciding (custom granule formulation) per disability-adjusted life years as a function of malaria
incidence for the provider and societal perspectives. The very cost-effective threshold is defined as a cost-effectiveness ratio below the per
capita Gross Domestic Product (GDP) of Tanzania ($599 USD), and the cost-effective threshold to three times the per capita GDP.
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tives, are unlikely to apply in settings where health systems
characteristics, treatment seeking behaviors, and wages
are drastically different. Second, health outcomes were not
discounted in this economic evaluation, in accordance
with the methodology adopted by the 2010 GBD update.
Discounting DALYs at 3%, however, would have yield a
net CER (society’s perspective) of $82, $528, and $1,040
per DALYaverted for the first, second, and third transmis-
sion scenario, respectively. This increase of the CER by a
factor of two highlights the impact of social value choices
in economic evaluation. Yet, even when discounting
health outcomes, larviciding remains below the cost-
effective threshold for all scenarios (and below the very-
cost effective threshold for scenarios #1 and #2). Third,
using other protective measures such as ITN, window
screening, and closed ceilings are believed to have syner-
gistic effects with the larviciding intervention [28]. Not
taking these synergies into account could underestimate
the population impact of larviciding and the cost-
effectiveness of the intervention. Finally, health insurance
coverage, which could affect CER for both the provider
and societal perspectives, was not taken into account.
Given that health coverage is relatively low in Dar es
Salaam, with only 7.8% of women and 5% of men aged
15–49 years of age having any form of insurance [52], this
omission is, however, unlikely to dramatically impact the
results.
In conclusion, this economic evaluation of the Dar es
Salaam UMCP larviciding programme has shown that,
according to commonly used GDP thresholds, this inter-
vention is very cost-effective in most transmission set-
tings where malaria incidence is above 110–116
infections per 1,000 per year (above 40 infections per
1,000 to be deemed cost effective). This study also lends
support for the Tanzanian National Malaria Control
Programme strategic plan to scale-up larviciding inter-
ventions by 2020 to selected urban areas of the country
[53]. Given limited health budgets, however, decision-
makers should still prioritize scaling-up ITN and IRS in
rural areas because larviciding interventions have been
shown to be more costly when the density of breeding
habitats is high and/or the population density is low
[17,18]. Once coverage of these interventions is satisfac-
tory in highly endemic areas, larviciding could be part of
an IVM approach for malaria control, if local conditions
warrant its use. This is especially true if other interven-
tions have achieved their maximum impact and/or if the
National Malaria Control Programme of a specific coun-
try wishes to move forward from malaria control to the
pre-elimination and elimination phases. Finally, this
study also highlights the lack of cost-effectiveness ana-
lyses for malaria control in urban areas of SSA, and it
remains unknown which combinations of interventions
(e.g., ITN, IRS, LSM) are most cost-effective in such
settings.
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